scispace - formally typeset
C

Chuanhai Cao

Researcher at University of South Florida

Publications -  132
Citations -  6167

Chuanhai Cao is an academic researcher from University of South Florida. The author has contributed to research in topics: Medicine & Antimicrobial. The author has an hindex of 39, co-authored 114 publications receiving 5219 citations. Previous affiliations of Chuanhai Cao include University of Pennsylvania.

Papers
More filters
Journal ArticleDOI

Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease

Rebecca Sims, +487 more
- 01 Sep 2017 - 
TL;DR: Three new genome-wide significant nonsynonymous variants associated with Alzheimer's disease are observed, providing additional evidence that the microglia-mediated innate immune response contributes directly to the development of Alzheimer's Disease.
Journal ArticleDOI

Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis

David C. Whitcomb, +201 more
- 01 Dec 2012 - 
TL;DR: Two associations at genome-wide significance identified and replicated at PRSS1-PRSS2 and X-linked CLDN2 are reported and could partially explain the high frequency of alcohol-related pancreatitis in men.
Journal ArticleDOI

Caffeine reverses cognitive impairment and decreases brain amyloid-β levels in aged Alzheimer's disease mice.

TL;DR: Even with pre-existing and substantial Abeta burden, aged APPsw mice exhibited memory restoration and reversal of AD pathology, suggesting a treatment potential of caffeine in cases of established AD.
Journal ArticleDOI

A novel Alzheimer disease locus located near the gene encoding tau protein

Gyungah Jun, +450 more
- 01 Jan 2016 - 
TL;DR: The authors' APOE-stratified GWAS is the first to show GWS association for AD with SNPs in the chromosome 17q21.31 region, and the finding in the stage 1 sample that AD risk is significantly influenced by the interaction of APOE with TMEM106B (P=1·6 × 10−7) is noteworthy, because TMEM 106B variants have previously been associated with risk of frontotemporal dementia.
Journal ArticleDOI

Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease.

TL;DR: Melatonin’s cognitive benefits could involve its anti‐Aβ aggregation, anti‐inflammatory, and/or antioxidant properties, and support for long‐term melatonin therapy as a primary or complementary strategy for abating the progression of Alzheimer disease.